Patents by Inventor Muthoni G. Kamau

Muthoni G. Kamau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTS OF ROR GAMMAt
    Publication number: 20230295087
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 8, 2020
    Publication date: September 21, 2023
    Inventors: Lalgudi S. Harikrishnan, Brian E. Fink, Patrice Gill, Lan-Ying Qin, Muthoni G. Kamau, Tram N. Huynh, Ashok Vinayak Purandare, Honghe Wan, Daniel O’Malley
  • AGONISTS OF ROR GAMMAt
    Publication number: 20230242478
    Abstract: The present invention is directed to compounds of the formula [INSERT CHEMICAL STRUCTURE HERE}] wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 3, 2023
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Brian E. Fink
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11667663
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 6, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lalgudi S. Harikrishnan, Muthoni G. Kamau, Xiao Zhu
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11660311
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 30, 2023
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11339185
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20220117995
    Abstract: The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 21, 2022
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Yufen Zhao, Lan-Ying Qin, Zheming Ruan, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200270298
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 30, 2018
    Publication date: August 27, 2020
    Inventors: Lalgudi S. HARIKRISHNAN, Muthoni G. Kamau, Xiao Zhu
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10744150
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 18, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Lan-ying Qin, Zheming Ruan, Yufen Zhao, Lalgudi S. Harikrishnan, Muthoni G. Kamau, Steven J. Walker
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200079815
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G, Kamau, Lalgudi S. Harikrishnan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10519187
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 31, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190248828
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • Carbazole compounds useful as bromodomain inhibitors
    Patent number: 10196387
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: February 5, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190030057
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 31, 2019
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Lan-ying Qin, Zheming Ruan, Yufen Zhao, Lalgudi S. Harikrishnan, Muthoni G. Kamau
  • Carbazole compounds useful as bromodomain inhibitors
    Patent number: 10053454
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: August 21, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
  • TGF?R antagonists
    Patent number: 9708316
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Robert M. Borzilleri, Liping Zhang, Kyoung S. Kim, Muthoni G. Kamau, Andrew J. Tebben, Yong Zhang, Andrew F. Donnell
  • CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS
    Publication number: 20170152248
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 13, 2017
    Publication date: June 1, 2017
    Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
  • TGF BETA R ANTAGONISTS
    Publication number: 20160176871
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 23, 2016
    Inventors: Brian E. Fink, Yufen Zhao, Robert M. Borzilleri, Liping Zhang, Kyoung S. Kim, Muthoni G. Kamau, Andrew J. Tebben
  • CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS
    Publication number: 20160009701
    Abstract: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Inventors: Michael A. Poss, David R. Tortolani, Ashok Vinayak Purandare, John S. Tokarski, Christopher P. Mussari, Muthoni G. Kamau, Dharmpal S. Dodd, Ashvinikumar V. Gavai, Daniel O'Malley, Tram N. Huynh, Wayne Vaccaro, Lalgudi S. Harikrishnan
  • Heterocyclic CETP inhibitors
    Patent number: 8642576
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: February 4, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • Pyrrolotriazine kinase inhibitors
    Patent number: 8445676
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: May 21, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, David B. Frennesson, Muthoni G. Kamau, Lalgudi S. Harikrishnan, Mark G. Saulnier